With more than 10 clinical trials and 20 years of clinical and real-world experience, the WATCHMAN™ Implant is the most studied and implanted left atrial appendage closure (LAAC) device.
Active WATCHMAN trials
CHAMPION-AF clinical trial
With over 500,000 patients implanted with the WATCHMAN platform, CHAMPION-AF extends Boston Scientific’s LAAC leadership by evaluating the WATCHMAN FLX LAAC Implant as a safe and effective first-line option versus non-vitamin K antagonist oral anticoagulants (NOACs) to reduce stroke risk.*
Learn more about the CHAMPION-AF trial
SIMPLAAFY clinical trial
SIMPLAAFY is a randomized controlled trial that will evaluate two monotherapy regimens vs. dual anti-platelet therapy (DAPT) after implant with the WATCHMAN FLX™ Pro Device in patients with atrial fibrillation (AFib). SIMPLAAFY will assess whether a less intensive drug regimen may help mitigate post-implant bleeding risk and provide other viable options for post-implant treatment.
Learn more about the SIMPLAAFY trial
First three-year data from NCDR-LAAO Registry
The NCDR-LAAO Registry analysis is a review of the first three years and over 38,000 WATCHMAN Implants.3 This analysis, The NCDR Left Atrial Appendage Occlusion (LAAO) Registry™: Review of the First 3 Years, was presented by Dr. James Freeman on March 29, 2020 at the ACC 2.0/WCC Virtual Experience. This analysis demonstrates that major in-hospital adverse event rates were in-line with those reported in the pivotal WATCHMAN Implant trials.
Learn more about the registry analysis
Pilot study
Meta-analyses confirmed that in cases of left atrial thrombus in non-rheumatic AFib patients, approximately 90% of them are in the LAA. This study assessed the feasibility of implanting a device in the LAA in patients with AFib to prevent thromboembolic stroke.9
The authors concluded that preliminary data suggest LAAC with WATCHMAN to be safe and feasible.
